Neurosense Therapeutics is trading 11% down at $0.39 amid broad risk-off selling on August 18, 2026.
- Nasdaq Composite and S&P 500 fell as technology shares retreated, Treasury yields climbed, and renewed U.S.-Iran tensions increased oil and inflation concerns.
- Reuters reported falling U.S. futures, elevated oil, and multi-year-high bond yields; no new company-specific announcement was identified.
- Weakness follows the August 13 CEO shareholder letter and upcoming reverse-split vote, neither confirmed as today’s direct catalyst.